cme group inc. - CME
CME
Close Chg Chg %
293.93 6.41 2.18%
Open Market
300.34
+6.41 (2.18%)
Volume: 1.12M
Last Updated:
Mar 26, 2026, 2:19 PM EDT
Company Overview: cme group inc. - CME
CME Key Data
| Open $295.61 | Day Range 294.08 - 300.85 |
| 52 Week Range 248.63 - 329.16 | Market Cap $105.41B |
| Shares Outstanding 358.63M | Public Float 357.07M |
| Beta 0.26 | Rev. Per Employee N/A |
| P/E Ratio 26.34 | EPS $11.18 |
| Yield 170.11% | Dividend $7.45 |
| EX-DIVIDEND DATE Mar 10, 2026 | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.36M |
CME Performance
| 1 Week | -4.36% | ||
| 1 Month | -8.00% | ||
| 3 Months | 6.22% | ||
| 1 Year | 12.09% | ||
| 5 Years | 41.01% |
CME Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
18
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | HOLD | Average Target Price | 311.857 | |
| Number of Ratings | 18 | Current Quarters Estimate | 3.106 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 12.04 | |
| Last Quarter’s Earnings | 2.77 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 11.20 | Next Fiscal Year Estimate | 12.708 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 12 | 15 | 15 |
| Mean Estimate | 3.11 | 3.03 | 12.04 | 12.71 |
| High Estimates | 3.59 | 3.12 | 12.79 | 13.56 |
| Low Estimate | 2.93 | 2.87 | 11.63 | 11.98 |
| Coefficient of Variance | 6.04 | 2.71 | 2.79 | 3.30 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 2 | 2 | 2 |
| HOLD | 5 | 4 | 7 |
| UNDERWEIGHT | 3 | 3 | 2 |
| SELL | 2 | 2 | 2 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Cme Group Inc. - CME
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cme Group Inc. - CME
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 18, 2026 | Hilda Harris Piell Sr MD & Chief HR Officer | 33,455 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 10,417,887.00 |
| Mar 18, 2026 | Lynne Fitzpatrick President and CFO | 26,428 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 8,229,679.20 |
| Mar 18, 2026 | Jack J. Tobin MD Chief Accounting Officer | 25,409 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 7,912,362.60 |
| Mar 18, 2026 | Jack J. Tobin MD Chief Accounting Officer | 25,588 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 7,968,103.20 |
| Mar 18, 2026 | Tim McCourt Sr MD Global Head Equity & FX | 12,202 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 3,799,702.80 |
| Mar 18, 2026 | Julie M. Winkler Sr MD Chief Commercial Officer | 30,110 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 9,376,254.00 |
| Mar 18, 2026 | Julie M. Winkler Sr MD Chief Commercial Officer | 33,768 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 10,515,355.20 |
| Mar 18, 2026 | Lynne Fitzpatrick President and CFO | 23,989 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 7,470,174.60 |
| Mar 18, 2026 | Kendal Vroman Chief Transformation Officer | 18,851 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 5,870,201.40 |
| Mar 18, 2026 | Kendal Vroman Chief Transformation Officer | 21,986 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 6,846,440.40 |
| Mar 18, 2026 | Lynne Fitzpatrick President and CFO | 23,913 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 7,446,508.20 |
| Mar 18, 2026 | Tim McCourt Sr MD Global Head Equity & FX | 15,012 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 4,674,736.80 |
| Mar 18, 2026 | Hilda Harris Piell Sr MD & Chief HR Officer | 36,494 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 11,364,231.60 |
| Mar 18, 2026 | Tim McCourt Sr MD Global Head Equity & FX | 12,108 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 3,770,431.20 |
| Mar 18, 2026 | Derek L. Sammann Sr MD Gl Hd Commodities Mkts | 13,312 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 4,145,356.80 |
| Mar 18, 2026 | Derek L. Sammann Sr MD Gl Hd Commodities Mkts | 16,939 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 5,274,804.60 |
| Mar 18, 2026 | Sunil Cutinho Chief Information Officer | 27,244 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 8,483,781.60 |
| Mar 18, 2026 | Sunil Cutinho Chief Information Officer | 23,586 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 7,344,680.40 |
| Mar 18, 2026 | Terrence A. Duffy Chairman and CEO; Director | 90,630 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $311.4 per share | 28,222,182.00 |
| Mar 18, 2026 | Terrence A. Duffy Chairman and CEO; Director | 118,496 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $311.4 per share | 36,899,654.40 |
Cme Group Inc. in the News
Chicago's corporate exodus serves as backdrop to DNC
Chicago has seen several high-profile departures of corporations moving their headquarters or significant portions of their operations out of the city in recent years.
CME denies CBOE merger report
Derivatives exchange giant CME Group has forcefully denied a report that it is in talks to acquire smaller Cboe Global Markets.